Development status: Approved, off-patent (not available in most countries)

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive (incl. Mycobacterium tuberculosis) and Gram-negative bacteria

Additional information: Streptomyces natural compound, closely related to amikacin. Veterinary use, human use in tuberculosis and topical formulations